Collegium Insider Sale Signals Strategic Risk‑Management, Not Distress
Collegium insider sale shows a measured risk‑management move while its CNS & respiratory pipeline gains FDA fast‑track status, signaling potential upside once milestones hit.
- Collegium Pharmaceutical Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read